[New trends in the treatment of amyloidosis]

Med Clin (Barc). 2012 May 26;138(15):667-72. doi: 10.1016/j.medcli.2011.09.032. Epub 2011 Dec 22.
[Article in Spanish]

Abstract

Amyloidosis is a clinical disorder caused by extracellular deposition of proteins that are normally soluble as insoluble fibrils that damage different organs. More than 20 proteins can form amyloid deposits. All types of amyloid fibrils have a secondary structure with a β folded shape that is characteristic and makes them to adopt a green birefringence after stained with Congo red and viewed under cross-polarized light. Amyloidosis can be acquired or hereditary, systemic or localized, and are classified by the fibril precursor protein. Advances in the knowledge of the pathogenesis of amyloidosis allows the development of new diagnostic and therapeutical schemes that are currently under investigation.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Amyloid / chemistry
  • Amyloidosis / diagnosis
  • Amyloidosis / etiology
  • Amyloidosis / therapy*
  • Carboxylic Acids / therapeutic use
  • Humans
  • Immunotherapy / methods
  • Propane / analogs & derivatives
  • Propane / therapeutic use
  • Protein Conformation
  • Pyrrolidines / therapeutic use
  • Sulfonic Acids / therapeutic use

Substances

  • Amyloid
  • Carboxylic Acids
  • Pyrrolidines
  • R-1-(6-(R-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid
  • Sulfonic Acids
  • eprodisate
  • Propane